GlassScriptPhysician profile
Vannara Sakbun
NPI 1558335893
$2,817.49
in general payments reported to CMS, 2019-2025
36 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2020: $281 · 2021: $517 · 2022: $410 · 2023: $250 · 2024: $250 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $637.95 | 2019-2023 | Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $247.09 | 2019-2024 | Aptima |
| Daiichi Sankyo INC. | $204.69 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $179.29 | 2019-2025 | |
| Biogen, INC. | $147.54 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $123.20 | 2021-2024 | Veozah |
| Agile Therapeutics, INC. | $121.46 | 2021 | |
| Exeltis, USA INC. | $112.93 | 2020-2025 | Slynd |
| Myovant Sciences INC. | $103.91 | 2021-2022 | |
| Exact Sciences Corporation | $95.76 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $72.09 | 2022-2023 | Accrufer |
| Minerva Surgical, INC | $69.61 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $68.16 | 2019 | |
| Merck Sharp & Dohme LLC | $64.32 | 2019-2021 | |
| Pfizer INC. | $59.28 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $42.32 | 2022-2025 | Endosee |
| Duchesnay USA Incorporated | $40.77 | 2019 | |
| Dexcom, INC. | $40.46 | 2023-2024 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $32.98 | 2020-2021 | |
| Axonics, INC. | $32.14 | 2021-2022 | |
| Axsome Therapeutics, INC. | $32.05 | 2025 | Auvelity |
| Allergan, INC. | $29.84 | 2019 | |
| Therapeuticsmd, INC. | $27.39 | 2019-2022 | |
| Sage Therapeutics, LLC | $25.93 | 2019-2021 | |
| Argenx US, INC. | $25.28 | 2025 | Vyvgart |
| Lupin INC. | $24.61 | 2019 | |
| Davol INC. | $22.91 | 2020 | |
| Amag Pharmaceuticals, INC. | $18.29 | 2020 | |
| Avanos Medical | $17.26 | 2019 | |
| Kci USA, INC. | $16.74 | 2021 | |
| Amgen INC. | $15.26 | 2023 | Prolia, Evenity |
| Coloplast Corp | $15.20 | 2024 | |
| Novo Nordisk INC | $15.05 | 2022 | |
| Boston Scientific Corporation | $13.62 | 2019 | |
| Avion Pharmaceuticals | $11.51 | 2021 | |
| Organon LLC | $10.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vannara Sakbun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.